GC5107
Phase 3Biologic
GC5107 is one of 49 biologic programs targeting Immunodeficiency. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
53 competitors in Immunodeficiency
#DrugCompanyPhaseTrials
1Fuzeon
CConrado Roberto Hoffmann Filho
Approved
Adenocard
AstellasApproved
Rayos
RRoxane Laboratories
Approved
Viramune
Boehringer IngelheimApproved
Busulfex
Akero TherapeuticsApproved
Cabenuva
GSKPhase 3
Edurant Ped
WWim Janssens
Phase 3
B/F/TAF
GileadPhase 3
Immunoglobulin
SanofiPhase 3
Cellcept
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GC5107. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- GGC Biopharma Corp